Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Objective: Real-world medical cost avoidances from a US payer perspective were estimated when new oral anticoagulants (NOACs) are used instead of warfarin for the treatment of patients with venous thromboembolism (VTE). Methods: Reductions in real-world event rates of recurrent VTE and MB were obtained by applying rate reductions from the NOACs versus warfarin trials to the Worcester population. Incremental annual medical costs among patients with VTE and MB from a US payer perspective were obtained from the literature or claims databases. Differences in total medical costs for patients treated with NOACs versus warfarin were then estimated. Univariate and Monte Carlo sensitivity analyses were additionally carried out. Results: The annual total medical cost avoidances versus warfarin were greatest for VTE patients treated with apixaban (−US$4440 per patient-year [ppy]), followed by those treated with rivaroxaban (−US$2971 ppy), edoxaban (−US$1957 ppy), and dabigatran (−US$572 ppy). The medical cost avoidances remained consistent under sensitivity analyses. Conclusion: Based on real-world data, when any of the evaluated NOACs are used instead of warfarin for treatment of patients with acute VTE, annual medical costs are reduced. Of the NOACs, apixaban has the greatest real-world medical cost avoidance, as its use is associated with substantial reductions in both VTE and MB event rates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Four reports suggested that a DOAC is cost saving compared with warfarin, 99-102”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [99]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583 · cited 10×
“As real-world observational studies have shown patient populations with VTE markedly differ from those participating in clinical trials, it is important to predict medical cost differences among patients with VTE receiving different treatments in real-world settings.(6-14,17,19) The study of Lefebvre et al, from which…”
BackgroundMethodResultInfluentialBüller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353 · cited 10×
“As real-world observational studies have shown patient populations with VTE markedly differ from those participating in clinical trials, it is important to predict medical cost differences among patients with VTE receiving different treatments in real-world settings.(6-14,17,19) The study of Lefebvre et al, from which…”
BackgroundMethodResultInfluentialOral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324 · cited 10×
“As real-world observational studies have shown patient populations with VTE markedly differ from those participating in clinical trials, it is important to predict medical cost differences among patients with VTE receiving different treatments in real-world settings.(6-14,17,19) The study of Lefebvre et al, from which…”
BackgroundMethodResultInfluentialThe Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109 · cited 3×
“As real-world observational studies have shown patient populations with VTE markedly differ from those participating in clinical trials, it is important to predict medical cost differences among patients with VTE receiving different treatments in real-world settings.(6-14,17,19) The study of Lefebvre et al, from which…”
BackgroundResultEdoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869 · cited 10×
“As real-world observational studies have shown patient populations with VTE markedly differ from those participating in clinical trials, it is important to predict medical cost differences among patients with VTE receiving different treatments in real-world settings.(6-14,17,19) The study of Lefebvre et al, from which…”
BackgroundMethodResultInfluentialPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
The Epidemiology of Venous Thromboembolism in the Community
Heit, J. A. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.162545 · Cited by 778
Research works printed but not linked: 2
- White Paper. Deep vein thrombosis. Advancing awareness to protect patient lives. Public Health Leadership Conference on Deep-Vein Thrombosis, American Public Health Association; 2003. Web site. http://www.apha.org/NR/rdonlyres/A209F84A-7C0E-4761-9ECF-61D22E1E11F7/0/DVT_White_Paper.pdf. Accessed February 1, 2015.
- Amin A, 2015, J Med Econ
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus
Seliverstov, E. I., Lobastov, K. V., Ilyukhin, Е. А., Apkhanova, T. V., Akhmetzyanov, R. V., Akhtyamov, I. F., Barinov, V., Bakhmetiev, A. S., Belov, M. V., Александрович, Б. С., et al. (2023) · Journal of Venous Disorders · doi:10.17116/flebo202317031152 · Cited by 121
DOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 96
“positive cost savings and cost-effectiveness of DOACs in routine clinical practices [59–61], these may not be ap-”
BackgroundCohen, A. T., Hamilton, M., Bird, A., Mitchell, S. A., Li, S., Horblyuk, R. V., & Batson, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160064 · Cited by 74
“The use of NOACs, and apixaban in particular, may therefore result in improvements in the extended treatment of VTE [49, 50].”
BackgroundEdoxaban: A direct oral anticoagulant
Poulakos, M. N., Walker, J. N., Baig, U., & David, T. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150821 · Cited by 57
“patients.(50) Through univariate and Monte Carlo sensitivity analyses, the following estimates of PPY cost avoidance with the use of DOACs versus warfarin were derived: apixaban, $4440; rivaroxaban, $2971; edoxaban, $1957; and dabigatran, $572.”
Background
Metadata
- Authors
- Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M.
- Affiliations
- University of California, Irvine (US)
- Bristol-Myers Squibb (United States) (US)
- Pfizer (United States) (US)
- Novosys Health, Health Economics & Outcomes Research, Green Brook, NJ, USA
- Corresponding author
- Amin, Alpesh
- Venue
- Clinical and Applied Thrombosis/Hemostasis
- Publisher
- SAGE Publications
- Published
- 2015-05-19
- Volume
- 22
- Issue
- 1
- Pages
- 5-11
- ISSN
- 1076-0296 (ISSN-L)
- 1938-2723
- OpenAlex
- W1847190482
- Cited by
- 20
- References
- 17
- Citations by year
- 2025: 1 · 2023: 2 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 2 · 2016: 4 · 2015: 1
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Clinical and Applied Thrombosis/Hemostasis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- direct oral anticoagulants, warfarin, venous thromboembolism, apixaban, rivaroxaban, edoxaban, dabigatran, major bleeding, recurrent venous thromboembolism, payer perspective
- MeSH terms
- Administration, Oral, Anticoagulants, Costs and Cost Analysis, Humans, Monte Carlo Method, United States, Warfarin, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States. https://app.cochat.ai/papers/10.1177/1076029615585991
- The paper
- Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M. (2016). Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/1076029615585991
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.